Case: BIOCON LTD. Architecture a biotech assertive Reasons for success of Biocon Ltd. in the past: Sequential advance strategy: Biocon added businesses like enzymes, biopharmaceuticals, analysis casework and biologic development that were interlinked. Consolidation of amount skills: Biocon had circumscribed its amount abilities in enzymes (known to be the architecture blocks of biotech), accustomed a brand in biopharmaceuticals (which helped accomplish approved banknote flow) and partnered with all-around firms (serving as ablution pads for biologic development).
Biocon's Integrated Business Model: Biocon, forth with its subsidiaries – Syngene and Clinigene, handles the absolute lifecycle of a drug; appropriate from analysis to commercialization (it has atomic adeptness in commercialization). o Analysis Syngene Molecular Biology Synthetic Chemistry Biocon Microbial Fermentation Biodiversity Bioprocessing o Development Clinigene Analytic Analysis Analytic Development Analytic Trials o Commercialization Biocon Generics, capital contributor to revenue: Bulk of their revenues came from generics.
A all-encompassing biologic about amount 20 per cent to 80 per cent beneath because the artefact was not abounding with bequest costs of research, development, analytic trials and marketing. Apparent of Plafactor: Biocon anchored a U. S. apparent for a reactor it developed, accepted as plafactor. The apparent gave the aggregation absolute all-around rights to use and authorization the technology for the accomplish of drugs involving genetically engineered microorganisms in a solid-state fermenter.
Diversified and Specialized: From the company’s origins authoritative enzymes for the breweries industry, Biocon had broadcast and adapted into accompanying fields during the abutting two decades. Biocon specialized in four ample areas: enzymes, biopharmaceuticals, custom analysis and analytic research. Fermentation offered aggressive advantage: The accent of enzymes for Biocon lay in the actuality that the business was a springboard for one of the company’s aggressive advantages. Fermentation was a amount accomplishment that offered Biocon a advantage in date 3 of the amount alternation of biopharmaceuticals.
The company’s crumbling accommodation gave it both the adeptness to calibration up an automated action and the belvedere on which to accompany discovery-led growth. Threats to comestible this achievement in future: Added aggressive market: Every biotech amateur - big and small, was gluttonous a ballast in generics. The biopharmaceuticals space, in which Biocon had congenital a niche, was appropriately acceptable added awash and aggressive day by day. Alteration Authoritative Environment: The authoritative ambiance that had fabricated generics such an adorable area in India was changing.
The government of India had alien a full-fledged patents regime. In the past, the Indian government had accepted patents for the action of accomplishment a drug, not for the biologic itself. Apparent aegis of Statins: Biopharmaceuticals represented 80 per cent of Biocon’s turnover, with the assembly of APIs for statins accounting for 45 per cent of revenue. Statins would lose apparent aegis in 2008 in the United States. As a result, the dollar amount of the all-around bazaar for statins would compress from $22 billion to $3 billion.
There were additionally appraisement pressures from bargain Chinese competitors. Commercialization: Relative to the company’s alternative activities; Biocon had the atomic adeptness in this final date of biologic analysis and development. Investments were actuality fabricated in creating the accomplishment accommodation for automated scale-up. Commercialization would additionally crave acquiescence with accomplishment standards, deployment of a sales force and development of adeptness in business and promotions aimed at physicians and end-customers.
Greater appeal on Biocon’s banking resources: Biocon had operated for a continued time in the branch of commodities, characterized by business-to-business sales. Authoritative the alteration to biologic analysis and development would absorb developing adequacy in several key areas: architecture a portfolio of able biologic candidates to move through the development pipeline, activity administration abilities to facilitate this process, authoritative compliance, accomplishment and marketing. The charge to advance capabilities in these areas would abode greater appeal on Biocon’s banking resources.
Order a unique copy of this paper